CANONIC
CULTIVATED by SCIENCE

COMPANY PRESENATION

Forward Looking Statement

This presentation contains "forward-looking statements" relating to future events, and Canonic Ltd (the "Company") and its parent, Evogene Ltd. ("Evogene"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws, as amended. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "should", "planned", "estimated", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, as well as the capabilities of Evogene's and our technology.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation.Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

INTRODUCTION

OUR VISION

Provide tailored medical cannabis products to optimize consumer wellbeing.

OUR SOLUTION

Predict interactions between active cannabis chemical compounds and therapeutic effects on the human body, utilizing computational power, AI and extensive biological knowledge.

Global Cannabis Market

Legal Cannabis Worldwide: $46.8 Billion in 2025

Legend: United States, Canada, Europe, Latin America, Rest of World

Market Challenges

STABILITY
Substantial variations within varieties produce inconsistent products and therefore, inconsistent results

YIELD
Low yield of active compounds affects income per sq foot

SPECIFICITY
Significant knowledge gap prevents matching active compounds to therapeutic effects

The opportunity : using state-of-the-art plant genomics to overcome major market challenges

The opportunity
From Plant Genomics to Medical Cannabis Products

Plant genetics are at the basis of developing **premium cannabis varieties**

Premium varieties can lead to **novel medical cannabis products** addressing market challenges

TECHNOLOGY

Genomic Power – Improving Performance

The potential:
Improve plant traits through advanced breeding

Similarly to what various leading cultural crops, such as corn, have undergone via directed breeding, Cannabis can also be cultured into a desired crop with stable traits.

The challenges:

1. Match genomic elements to traits
2. Shorten development time

Wild Maze

Cultured Maze

# When Data Meets Computational Biology

Computational Genomics

Combining deep scientific know-how with Big Data and AI technology to tailor the plant genetics for improvement of plant traits and development of unique cannabis products

BIG DATA

Genomics

AI

# Big Data & AI – Transforming Data to Product

Plant genomics
database with $>10^9$ data points on > 200 plants

Proprietary cannabis genomic & chemical data on > 3000 lines

Pre-clinical data

BIG DATA

Gene Rator AI [1]

Computational genomics tools

AI

Products

CANONIC
SYNERGY
תפרחות קנביס רפואי
T20/04

CANONIC

Genomic Power Example – 20% Increase in THC Content

Developing next generation MetaYield+ products

By leveraging our unique proprietary know-how and database, within **12 months** we have:

- Improved the target trait by **20%**
- Reached **6-fold** increase in number of cannabis lines with > **20%** THC content

End-to-End R&D Capabilities

Large genetic & breeding collections

State of the art data collection tools

World-class computational genomics

Advanced-breeding facility

Fully equipped labs & tissue culture rooms

Certified propagation farm

PRODUCTS

Variety Families

MetaYield⁺

Stable enhancement of **total plant** compounds

Focus on **agronomic** and **consumer** traits

Increased active compounds
[e.g. Increased trichomes prevalence]

Optimize consumer traits
[e.g. inflorescence size, density, scent]

Ongoing Sales

Precise⁺

Stable enhancement of **specific active** compounds

Focus on **therapeutic** traits

Medical indication focus
[e.g. Pain & Inflammation]

Compound profile focus
[e.g. CBG, CBC]

Under Development

CANONIC

MetaYield+ – the 'G-nnovation' series

1st generation products were launched in Oct 2021

Product 1: G150

Scent

Pine
Lemon

Use

Day

IMC* category T15C3

18 % THC

High consumer rank

Active compounds

THC18%,CBD>0.1

Product 2: G200

Scent

Pine
Sweet

Use

Night

IMC* category T20C4

19 % THC

High consumer rank

Active compounds

THC19%,CBD>0.1

*IMC- Israel Medical Cannabis agency in the Ministry of Health

CANONIC

Precise⁺: Medical Indication Focus (under development)

PRODUCT 1

- **Indication:** Inflammation
- **Pre-clinical study:** Hadassah medical center
- **Status:** product development
- **Expected launch:** 2024
- **Target market size in 2024*:** Israel $115M, EU $300M

PRODUCT 2

- **Indication:** Pain
- **Pre-clinical study:** Migal research center
- **Status:** product development
- **Expected launch:** 2024
- **Target market size in 2024*:** Israel $280 M, EU $750M

*Company estimate, based on current market sale prices and data published by Israeli Health Ministry regarding number of medical cannabis users in Israel and by Prohibition Partners in The European Cannabis Report Feb 2020.

CANONIC

BUSINESS MODEL

Cannabis Value Chain – Seed to Sale

Powered by Genomics

ACTIVITY

Varieties Development	Seeds & Seedling Production	Cannabis Cultivation	Manufacturing	Distribution	Sales & Marketing	Patients
R&D Facilities	Propagation Farms	Cultivators	Extraction & Formulation	Regional Distributors	B2B2C Marketing to Pharmacies	

SUMMARY

Company Milestones

Value creation

- 2019 — Infrastructure, Genetic collection ✓
- 2020 — Go to Market- IL ✓
- 2021 — Initial sales-IL ✓
- 2022 — Go to Market- EU ✓
- 2023 — Expending sales-IL
- 2024 — Initial sales-EU
- 2025 and onward — Initial sales-WW

Time

| Target Markets	IL	IL, EU	Worldwide

Summary

- **Canonic's distinct market advantage** is in mapping, decoding and stabilizing cannabis genetics for improved wellbeing products.

- Canonic holds exclusive rights to Evogene's (NASDAQ, TASE: EVGN) state-of-the-art **computational genomics technology,** for product development.

- **Canonic's first two products, G-150 and G-200,** were launched in Israel in Oct 2021.

- **Next-generation products,** initiated launch in Israel in Oct 2022, focus on the market needs for:

  a) Rich THC and enriched with a high proportion of terpenes

  b) Balanced THC/CBD

  c) Rare minor cannabinoids.

- Canonic aims to enter the **EU market** during 2024.

CANONIC

CULTIVETED by SCIENCE

THANK YOU